Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!

BCDA Insider Trading (BioCardia)

Insider Ownership Percentage: 22.10%
Insider Buying (Last 12 Months): $19,164.00
Insider Selling (Last 12 Months): $16,954.35

BioCardia Insider Trading History Chart

This chart shows the insider buying and selling history at BioCardia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCardia Share Price & Price History

Current Price: $3.44
Price Change: Price Increase of +0.18 (5.52%)
As of 07/28/2021 01:56 PM ET

This chart shows the closing price history over time for BCDA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
One Stock You Should Watch
Tiny stock is straddling not one but two huge markets – read our report to learn more.
Learn more.

BioCardia Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2020Peter AltmanCEOBuy1,000$2.49$2,490.00203,200View SEC Filing Icon  
11/27/2020Peter AltmanCEOBuy3,200$2.37$7,584.00203,200View SEC Filing Icon  
11/12/2020Peter AltmanCEOBuy2,000$2.07$4,140.00205,900View SEC Filing Icon  
11/10/2020Peter AltmanCEOBuy2,500$1.98$4,950.00203,900View SEC Filing Icon  
11/2/2020Eric DuckersInsiderSell8,435$2.01$16,954.3512,088View SEC Filing Icon  
6/19/2020Jim L AllenDirectorBuy142,850$2.10$299,985.00668,200View SEC Filing Icon  
3/24/2020Peter AltmanCEOBuy1,200$2.90$3,480.00171,911View SEC Filing Icon  
3/19/2020Peter AltmanCEOBuy400$2.95$1,180.00170,711View SEC Filing Icon  
3/12/2020Peter AltmanCEOBuy3,400$3.15$10,710.00166,811View SEC Filing Icon  
8/2/2019Simon H StertzerDirectorBuy166,666$6.00$999,996.00View SEC Filing Icon  
6/5/2019Peter AltmanInsiderBuy2,000$1.02$2,040.00View SEC Filing Icon  
5/28/2019Peter AltmanInsiderBuy200$1.28$256.00View SEC Filing Icon  
5/17/2019Peter AltmanInsiderBuy2,100$1.15$2,415.00View SEC Filing Icon  
5/1/2019Peter AltmanInsiderBuy11,000$1.08$11,880.00View SEC Filing Icon  
2/13/2019Peter AltmanInsiderBuy50$1.59$79.50View SEC Filing Icon  
12/24/2018Phillip Md Et Al FrostMajor ShareholderBuy2,000,000$0.75$1,500,000.00View SEC Filing Icon  
12/24/2018Simon H StertzerDirectorBuy3,333,332$0.75$2,499,999.00View SEC Filing Icon  
11/29/2018Simon H StertzerDirectorBuy1,000$2.10$2,100.00View SEC Filing Icon  
11/16/2018Peter AltmanInsiderBuy6,400$2.34$14,976.00View SEC Filing Icon  
11/13/2018Peter AltmanInsiderBuy3,900$2.16$8,424.00View SEC Filing Icon  
11/13/2018Simon H StertzerDirectorBuy1,000$2.10$2,100.00View SEC Filing Icon  
11/9/2018Peter AltmanInsiderBuy500$2.50$1,250.00View SEC Filing Icon  
11/5/2018David McclungCFOBuy1,600$2.56$4,096.00View SEC Filing Icon  
11/2/2018Peter AltmanInsiderBuy400$2.52$1,008.00View SEC Filing Icon  
11/2/2018Simon H StertzerDirectorBuy2,000$2.53$5,060.00View SEC Filing Icon  
10/30/2018Peter AltmanInsiderBuy300$2.55$765.00View SEC Filing Icon  
10/26/2018Peter AltmanInsiderBuy3,850$2.36$9,086.00View SEC Filing Icon  
10/12/2018David McclungCFOBuy500$2.64$1,320.00View SEC Filing Icon  
10/11/2018Simon H StertzerDirectorBuy1,000$2.70$2,700.00View SEC Filing Icon  
9/25/2018David McclungCFOBuy2,850$2.45$6,982.50View SEC Filing Icon  
9/21/2018Simon H StertzerDirectorBuy1,000$2.43$2,430.00View SEC Filing Icon  
9/20/2018Peter AltmanInsiderBuy1,100$1.74$1,914.00View SEC Filing Icon  
9/18/2018Peter AltmanInsiderBuy700$1.59$1,113.00View SEC Filing Icon  
9/18/2018Simon H StertzerDirectorBuy5,000$1.50$7,500.00View SEC Filing Icon  
9/12/2018Peter AltmanInsiderBuy1,600$1.37$2,192.00View SEC Filing Icon  
9/5/2018Peter AltmanInsiderBuy5,000$1.33$6,650.00View SEC Filing Icon  
8/27/2018Peter AltmanInsiderBuy1,500$1.46$2,190.00View SEC Filing Icon  
See Full Table
Insider Buying at BioCardia?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for BioCardia and related companies.

SEC Filings (Institutional Ownership Changes) for BioCardia (NASDAQ:BCDA)

18.57% of BioCardia stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BCDA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

BioCardia Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/19/2021Squarepoint Ops LLC46,945$0.20M0.0%N/A0.280%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC305,200$1.33M0.0%N/A1.817%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC62,168$0.27M0.0%+175.6%0.370%Search for SEC Filing on Google Icon
5/12/2021CM Management LLC313,100$1.36M1.0%+36.1%1.864%Search for SEC Filing on Google Icon
2/9/2021Bank of New York Mellon Corp16,294$56K0.0%N/A0.131%Search for SEC Filing on Google Icon
2/5/2021CM Management LLC230,000$0.80M0.7%N/A1.851%Search for SEC Filing on Google Icon
8/17/2020Jane Street Group LLC14,688$35K0.0%N/A0.214%Search for SEC Filing on Google Icon
8/14/2020Captrust Financial Advisors659,179$1.62M0.0%N/A9.626%Search for SEC Filing on Google Icon
8/14/2020Advisor Group Holdings Inc.85,002$0.20M0.0%-7.7%1.241%Search for SEC Filing on Google Icon
5/18/2020Advisor Group Holdings Inc.92,083$0.31M0.0%N/A1.349%Search for SEC Filing on Google Icon
11/27/2019Millennium Management LLC41,978$0.14M0.0%N/A0.615%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
BioCardia logo
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Read More on BioCardia

Today's Range

Now: $3.44
Low: $3.44
High: $3.44

50 Day Range

MA: $4.05
Low: $3.26
High: $4.99

52 Week Range

Now: $3.44
Low: $1.91
High: $8.60


1 shs

Average Volume

51,543 shs

Market Capitalization

$57.76 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of BioCardia?

BioCardia's top insider investors include:
  1. Jim L Allen (Director)
  2. Peter Altman (CEO)
  3. Eric Duckers (Insider)
  4. Simon H Stertzer (Director)
The Only Futures Trading Guide You’ll Ever Need
Regardless of your level of futures trading prowess, our Technical Analysis Guide has something to help you succeed in today’s futures markets.
Download your FREE Technical Analysis Trading Guide Today!